European Pharmaceutical Review
AUGUST 15, 2022
According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK. First dose measles coverage dropped to 81 percent in 2021, the lowest level since 2008, meaning 24.7
STAT
JANUARY 12, 2023
SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 14, 2021
As we come up on a year and a half of the COVID-19 pandemic, with the global roll out of vaccines slowly gathering pace and big pharma riding high in the opinion charts, the biopharmaceutical sector would do well to learn lessons from the banks. Compliance systems by themselves are not enough. Of course, having rules is necessary.
pharmaphorum
JANUARY 19, 2023
When Milburn and Blair introduced competition in 2004-2008 it did start to make a difference.” Since 2008, the budget for NHS has grown 1% and the market 4%. The vaccine programme is the best example,” Lord Prior said. Highly unlikely.” Berry asked whether that included incentives or penalties.
Pharmaceutical Technology
JULY 23, 2008
The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “You can get vaccines now to prevent cervical cancer. “And there’s a tremendous opportunity to meet their needs.”
pharmaphorum
SEPTEMBER 18, 2020
In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 In April 2008, AstraZeneca also reached an agreement with Ranbaxy, an Indian generic drugmaker, allowing it to produce a generic version of Nexium starting in May 2014.
pharmaphorum
NOVEMBER 16, 2020
In his final message as head of the EMA, Rasi said the number of COVID-19 drugs and vaccines being developed by pharma companies is “encouraging,” and pointing to the agency’s pivotal role “in reviewing the available data packages to ensure that our usual high standards of safety, efficacy and quality are achieved and upheld.”.
Expert insights. Personalized for you.
98 
Let's personalize your content